antihemophilic factor recombinant (Rx)

Hemophilia A, Congenital

Indicated for prevention and control of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A (congenital Factor VIII deficiency)

Dosage (IU) = Body Weight (kg) × Desired Factor VIII level increase (IU/dL or % normal) × 0.5 (IU/kg per IU/dL)

Bleeding episodes

• Mild/moderate hemorrhage

  • Eloctate: 20-30 IU/kg IV to achieve factor VIII level of 40% to 60% of normal for the treatment of joint, superficial muscle/no neurovascular compromise (except iliopsoas), deep laceration and renal, superficial soft tissue, or mucous membrane bleeding; repeat q24-48hr until resolved
  • Advate, Helixate FS, Kogenate FS (initial): 10-20 units/kg IV to achieve factor VIII level of 20-40% of normal for the treatment of early hemarthrosis and minor muscle or oral bleed; may repeat dose q12-24hr x1-3 days if evidence of further bleeding
  • Recombinate, Xyntha: A dose sufficient to achieve factor VIII level of 20-40% of normal for the treatment of early hemarthrosis, muscle bleeding, or oral bleeding episode; may repeat dose q12-24hr x1-3 days if evidence of further bleeding
  • Nuwiq (mild): A dose sufficient to achieve factor VIII activity of 20-40% of normal for superficial muscle or soft tissue and oral bleeds; may repeat dose q12-24hr for at least 1 day, until bleeding episode resolved
  • Adynovate (mild): 10-20 IU/kg IV to achieve factor VIII activity of 20-40% of normal for superficial muscle or soft tissue and minor oral bleeds; may repeat dose q12-24hr for at least 1 day, until bleeding episode resolved
  • Kovaltry (mild): A dose sufficient to achieve factor VIII activity of 20-40% of normal for early hemarthrosis, minor muscle bleeding, or oral bleeds; may repeat dose q12-24hr for at least 1 day, until bleeding episode resolved
  • Afstyla (mild): A dose sufficient to achieve factor VIII activity of 20-40% of normal for early hemarthrosis, minor muscle bleeding, or oral bleeds; may repeat dose q12-24hr for at least 1 day, until bleeding episode resolved
  • Jivi (mild): 10-20 IU/kg IV to achieve factor VIII activity of 20-40% of normal for early hemarthrosis, superficial muscle or soft tissue and minor oral bleeds; may repeat dose q24-48hr until bleeding episode resolved
  • Esperoct (mild): 40 IU/kg; 1 dose is typically sufficient

• Moderate hemorrhage

  • Advate: 15-30 units/kg IV to achieve factor VIII level of 30-60% of normal for the treatment of moderate bleeding into muscles, bleeding into the oral cavity, definite hemarthroses, and known trauma; may repeat dose q12-24hr x1-3 days if evidence of further bleeding
  • Eloctate: 20-30 IU/kg IV to achieve factor VIII level of 40-60% of normal for the treatment of joint, superficial muscle/no neurovascular compromise (except iliopsoas), deep laceration and renal, superficial soft tissue, or mucous membrane bleeding; repeat q24-48hr until resolved
  • Helixate FS, Kogenate FS (initial): 15-20 units/kg IV to achieve factor VIII level of 30-60% of normal for the treatment of moderate bleeding into muscles, bleeding into the oral cavity, definite hemarthroses, and known trauma; may repeat dose q12-24hr x1-3 days if evidence of further bleeding
  • Recombinate: A dose sufficient to achieve factor VIII level of 30-60% of normal for the treatment of more extensive hemarthrosis, muscle bleeding, or hematoma; repeat q12-24hr x3 days or more
  • Xyntha: A dose sufficient to achieve factor VIII level of 30-60% of normal for the treatment of hemorrhages into muscles, mild head trauma, and hemorrhages into oral cavity; repeat q12-24hr x3-4 days or until adequate local hemostasis is achieved
  • Nuwiq: A dose sufficient to achieve factor VIII activity of 30-60% of normal for hemorrhage into muscles, into oral cavity, hemarthrosis, or known trauma; may repeat dose q12-24hr for at least 3-4 day, until bleeding episode resolved
  • Adynovate: 15-30 IU/kg IV to achieve factor VIII activity of 30-60% of normal for moderate hemorrhage in oral cavity, definite hemarthroses, and known trauma; may repeat dose q12-24hr until bleeding episode resolved
  • Kovaltry: A dose sufficient to achieve factor VIII activity of 30-60% of normal for more extensive hemarthrosis, muscle bleeding or hematoma; may repeat dose q12-24hr for at least 3-4 day, until bleeding episode resolved
  • Afstyla: A dose sufficient to achieve factor VIII activity of 30-60% of normal for more extensive hemarthrosis, muscle bleeding or hematoma; may repeat dose q12-24hr for at least 3-4 day, until bleeding episode resolved
  • Jivi: 15-30 IU/kg IV to achieve factor VIII activity of 30-60% of normal for more extensive hemarthrosis, muscle bleeding, or hematoma; may repeat dose q24-48hr until bleeding episode resolved
  • Esperoct: 40 IU/kg; an additional dose may be administered after 24 hr

• Severe hemorrhage

  • Advate: 30-50 units/kg IV to achieve factor VIII plasma level of 60-100% of normal for treatment of significant GI bleeding; intracranial, intra-abdominal, or intrathoracic bleeding; CNS bleeding; bleeding in the retropharyngeal or retroperitoneal spaces; or iliopsoas sheath, factures, and head trauma; repeat q8-24hr until bleeding episode resolved
  • Eloctate: 40-50 IU/kg IV to achieve factor VIII level of 80-100% of normal for the treatment of life or limb threatening hemorrhage, iliopsoas and deep muscle with neurovascular injury, and retroperitoneum, intracranial, or GI bleeding; repeat q12-24hr until bleeding resolved (typically 7-10 days)
  • Helixate FS, Kogenate FS: 40-50 units/kg IV to achieve factor VIII level of 80-100% of normal for the treatment of intracranial, intra-abdominal, or intrathoracic bleeding; GI bleeding; CNS bleeding; bleeding in the retroperitoneal or retropharyngeal spaces or iliopsoas sheath; fractures; and head trauma; repeat with 20-25 units/kg q8-12hr until bleeding episode resolved
  • Recombinate: A dose sufficient to achieve factor VIII level of 60-100% of normal for the treatment of life-threatening bleeding episodes, such as head injury, throat bleeding, or severe abdominal pain; repeat q8-24hr until bleeding episode resolved
  • Xyntha: A dose sufficient to achieve factor VIII level of 60-100% of normal for GI bleeding; intracranial, intra-abdominal, or intrathoracic hemorrhages; and fractures; repeat q8-24hr until bleeding episode resolved
  • Nuwiq: A dose sufficient to achieve factor VIII activity of 60-100% of normal for Intracranial, intraabdominal, GI, or intrathoracic bleeds, central nervous system bleeds, bleeding in retropharyngeal spaces or iliopsoas sheath, eyes/retina, fractures or head trauma; may repeat dose 8-24 hr until bleeding risk resolved
  • Adynovate: 30-50 IU/kg IV to achieve factor VIII activity of 60-100% of normal for severe hemorrhage including GI bleeding, intracranial, intraabdominal or intrathoracic, CNS, bleeding in the retropharyngeal or retroperitoneal spaces or iliopsoas sheath, fractures, head trauma; may repeat dose q8-24hr until bleeding episode resolved
  • Kovaltry: A dose sufficient to achieve factor VIII activity of 60-100% of normal for intracranial, intraabdominal, GI, or intrathoracic bleeds, central nervous system bleeds, bleeding in retropharyngeal spaces or iliopsoas sheath, life or limb threatening hemorrhage; may repeat dose 8-24 hr until bleeding risk resolved
  • Afstyla: A dose sufficient to achieve factor VIII activity of 60-100% of normal for intracranial, intraabdominal, GI, or intrathoracic bleeds, central nervous system bleeds, bleeding in retropharyngeal spaces or iliopsoas sheath, life or limb threatening hemorrhage; may repeat dose 8-24 hr until bleeding risk resolved
  • Jivi: 30-50 IU/kg IV to achieve factor VIII activity of 60-100% of normal for major hemorrhage including GI bleeding, intracranial, intraabdominal or intrathoracic, CNS, bleeding in the retropharyngeal or retroperitoneal spaces or iliopsoas sheath, live- or limb-threatening hemorrhage; may repeat dose q8-24hr until bleeding episode resolved
  • Esperoct: 50 IU/kg; additional doses may be administered ~q24hr

Perioperative management

• Minor surgery

  • Advate: 30-50 units/kg IV as a single IV bolus infusion beginning within 1 hr of the operation to achieve factor VIII level of 60-100% of normal for minor surgery, including tooth extraction; may repeat dosage q12-24hr as needed to control bleeding (for dental procedures, adjunctive therapy may be considered)
  • Eloctate: 25-40 units/kg IV to achieve factor VIII level of 50-80% of normal for minor surgery, including tooth extraction; may repeat dosage q24hr for at least 1 day until healing is achieved
  • Helixate FS, Kogenate FS: 15-30 units/kg IV to achieve factor VIII level of 30-60% of normal for minor surgery, including tooth extraction; may repeat dosage q12-24hr until bleeding is resolved
  • Recombinate: 60-80 units/kg IV to achieve adequate factor VIII level for minor surgery, including tooth extraction; a single infusion plus oral antifibrinolytic therapy within 1 hr is sufficient in ~70% of cases
  • Xyntha: An IV dose sufficient to achieve Factor VIII activity within 30-60% of normal q12-24hr for 3-4 days or until adequate local hemostasis is achieved; for tooth extraction, a single infusion plus oral antifibrinolytic therapy within 1 hr may be sufficient
  • Nuwiq: An IV dose sufficient to achieve Factor VIII activity within 80-100% of normal pre- and postoperatively; may repeat q24hr for least 1 day until healing is achieved
  • Kovaltry: An IV dose sufficient to achieve Factor VIII activity within 30-60% of normal pre- and postoperatively; may repeat q24hr for least 1 day until healing is achieved
  • Afstyla: An IV dose sufficient to achieve Factor VIII activity within 30-60% of normal pre- and postoperatively; may repeat q24hr for least 1 day until healing is achieved
  • Jivi: 15-30 IU/kg IV to achieve factor VIII level of 30-60% of normal for minor surgery (eg, tooth extraction); may repeat dosage q24hr for at least 1 day until healing is achieved
  • Esperoct: 50 IU/kg; additional dose(s) may be administered after 24 hr if necessary

• Major surgery

  • Advate: 40-60 units/kg IV preoperatively to achieve factor VIII level of 80-120% of normal pre- and postoperatively for major surgery, including intracranial, intra-abdominal, or intrathoracic surgery, and joint replacement surgery; repeat q8-24hr, depending on the desired level of factor VIII and state of wound healing
  • Eloctate: 40-60 units/kg IV preoperatively to achieve factor VIII level of 80-120% of normal pre- and postoperatively for major surgery, including intracranial, intra-abdominal, and joint replacement surgery; repeat dose of 40-50 units/kg after 8-24hr and then q24hr until adequate wound healing, then continue therapy for at least 7 days to maintain a Factor VIII activity within the target range
  • Helixate FS, Kogenate FS: 50 units/kg IV preoperatively to achieve factor VIII level of 100% of normal perioperatively for major surgery, including tonsillectomy, inguinal herniotomy, synovectomy, total knee replacement, craniotomy, osteosynthesis, trauma; repeat dose q6-12hr to maintain a Factor VIII activity within the target range until healing is complete
  • Recombinate: 80-100 units/kg IV preoperatively and postoperatively for major surgery; repeat dose q8-24hr depending on the state of healing
  • Xyntha: An IV dose sufficient to achieve Factor VIII activity within 60-100% of normal q8-24hr until threat is resolved, or in the case of surgery, until adequate local hemostasis and wound healing are achieved
  • Nuwiq: An IV dose sufficient to achieve Factor VIII activity within 30-60% of normal pre- and postoperatively for major surgery including intracranial, intraabdominal, or joint replacement therapy; may repeat q8-24hr until adequate wound healing, then continue therapy for at least another 7 days to maintain a Factor VIII activity of 30-60% (IU/dL)
  • Kovaltry: An IV dose sufficient to achieve Factor VIII activity within 80-100% of normal pre- and postoperatively for major surgery including intracranial, intraabdominal, intrathoracic, or joint replacement therapy; may repeat q8-24hr until adequate wound healing, then continue therapy for at least another 7 days to maintain a Factor VIII activity of 30-60% (IU/dL)
  • Afstyla: An IV dose sufficient to achieve Factor VIII activity within 80-100% of normal pre- and postoperatively for major surgery including intracranial, intraabdominal, intrathoracic, or joint replacement therapy; may repeat q8-24hr until adequate wound healing, then continue therapy for at least another 7 days to maintain a Factor VIII activity of 30-60% (IU/dL)
  • Jivi: 40-50 IU/kg IV to achieve factor VIII level of 80-100% of normal for major surgery (eg, intracranial, intra-abdominal, or joint replacement); may repeat dosage q12-24hr for at least 1 day until adequate wound healing complete, then continue therapy for at least another 7 days to maintain Factor VIII activity of 30-60% (IU/dL)
  • Esperoct: 50 IU/kg; additional doses can be administered ~q24hr for the first week and then ~q48hr until wound healing has occurred

Routine prophylaxis dose

• NovoEight: 20-50 IU/kg IV 3x/week, OR 20-4 IU/kg IV every other day
• Kogenate FS: 25 IU/kg IV 3x/week
• Advate: 20-50 IU/kg IV every other day, OR every 3rd day dosing targeted to maintain FVIII trough levels ≥1%
• Eloctate: 50 IU/kg IV q4days; adjust based on patient response (range: 24-65 IU/kg at 3-5 day intervals)
• Nuwiq: 30-40 IU/kg IV every other day
• Adynovate: 40-50 IU/kg IV 2x/week; adjust dose based on clinical response
• Kovaltry (adults and adolescents): 20-40 IU/kg IV 2-3 x/week
• Afstyla (adults and adolescents): 20-50 IU/kg IV 2-3 times per week
• Jivi: 30-40 IU/kg IV 2x/week; based on bleeding episodes, may adjust to 45-60 IU/kg q5days; may further individually adjust to less or more frequent dosing
• Esperoct: 50 IU/kg IV q4days; may further individually adjust to less or more frequent dosing

Hemophilia A, Acquired

Obizur: Porcine sequence product indicated for treatment of bleeding episodes in adults with acquired hemophilia

Initial: 200 units/kg; infuse IV at rate of 1-2 mL/min

Subsequent dosing

• May repeat q4-12hr
• Titrate dose and frequency of administration based on factor VIII recovery levels and individual clinical response
• Maintain the factor VIII activity within the target range; plasma levels of factor VIII should not exceed 200% of normal or 200 units/dL

FVIII level required

• Minor/moderate, superficial muscle, no neurovascular compromise, and joint: 50-100 U/dL
• Major, moderate to severe IM bleeding, retroperitoneal, GI, intracranial:
• -Acute major bleed: 100-200 U/dL
• -After acute major bleed controlled (if required): 50-100 U/dL

Limitations of use

• Safety and efficacy not established in patients with a baseline antiporcine factor VIII inhibitor titer >20 BU
• Not indicated for the treatment of congenital hemophilia A or von Willebrand disease

Dosing Considerations

Advate, Kovaltry, Xyntha: Recombinant, plasma/albumin-free method products

Obizur: Recombinant, porcine sequence product

Nuwiq: B-domain deleted recombinant FVIII derived from a human cell-line, not chemically modified or fused with another protein

Jivi: Not indicated for previously untreated patients or for treating von Willebrand disease

The amount of recombinant Factor VIII (in international units [IU]) is specified on each vial for the various products

Hemophilia A, Congenital

Indicated for prevention and control of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A (congenital Factor VIII deficiency)

Dosage (IU) = Body Weight (kg) × Desired Factor VIII Increase (IU/dL or % normal) × 0.5 (IU/kg per IU/dL)

Bleeding episodes, FVIII level required

• Mild hemorrhage: 20-40 IU/dL peak (700-1400 IU for 70 kg); begin infusions q12-24hr x 1-3 days until resolved
• Moderate hemorrhage: 30-60 IU/dL peak (1050-2100 IU for 70 kg); repeat infusions q12-24hr x 3 days or more until resolved
• Severe/life-threatening hemorrhage: 60-100 IU/dL peak (2100-3500 IU for 70 kg); repeat infusions q8-24hr until resolved

Bleeding episodes (Eloctate)

• Mild/moderate hemorrhage: 20-30 IU/kg IV; repeat q24-48hr (age <6 yr give q12-24hr) until resolved; 40-60 IU/dL FVIII level required
• Severe hemorrhage: 40-50 IU/kg IV; repeat q12-24hr (age <6 yr give q8-24hr) until resolved (~7-10 days); 80-100 IU/dL FVIII level required

Bleeding episodes (Nuwiq)

• Aged 2-17 years

  • Mild hemorrhage: A dose sufficient to achieve factor VIII activity of 20-40% of normal for superficial muscle or soft tissue and oral bleeds; may repeat dose q12-24hr for at least 1 day, until bleeding episode resolved
  • Moderate hemorrhage: A dose sufficient to achieve factor VIII activity of 30-60% of normal for hemorrhage into muscles, into oral cavity, hemarthrosis, or known trauma; may repeat dose q12-24hr for at least 3-4 day, until bleeding episode resolved
  • Severe hemorrhage: A dose sufficient to achieve factor VIII activity of 60-100% of normal for Intracranial, intraabdominal, GI, or intrathoracic bleeds, central nervous system bleeds, bleeding in retropharyngeal spaces or iliopsoas sheath, eyes/retina, fractures or head trauma; may repeat dose 8-24 hr until bleeding risk resolved

Bleeding episodes (Adynovate)

• Children (<12 years) have demonstrated higher clearance, a shorter half-life, and lower incremental recovery of factor VIII compared to adults; dose adjustment or more frequent dosing based on per kg body weight may be needed in this population
• Mild hemorrhage: 10-20 IU/kg to achieve factor VIII activity of 20-40% of normal for superficial muscle or soft tissue and minor oral bleeds; may repeat dose q12-24hr for at least 1 day, until bleeding episode resolved
• Moderate hemorrhage: 15-30 IU/kg to achieve factor VIII activity of 30-60% of normal for moderate hemorrhage in oral cavity, definite hemarthroses, and known trauma; may repeat dose q12-24hr until bleeding episode resolved
• Severe hemorrhage: 30-50 IU/kg to achieve factor VIII activity of 60-100% of normal for severe hemorrhage including GI bleeding, intracranial, intraabdominal or intrathoracic, CNS, bleeding in the retropharyngeal or retroperitoneal spaces or iliopsoas sheath, fractures, head trauma; may repeat dose q8-24hr until bleeding episode resolved

Bleeding episodes (Kovaltry)

• Aged ≤12 years

  • Mild hemorrhage: A dose sufficient to achieve factor VIII activity of 20-40% of normal for early hemarthrosis, minor muscle bleeding, or oral bleeds; may repeat dose q12-24hr for at least 1 day, until bleeding episode resolved
  • Moderate hemorrhage: A dose sufficient to achieve factor VIII activity of 30-60% of normal for more extensive hemarthrosis, muscle bleeding or hematoma; may repeat dose q12-24hr for at least 3-4 day, until bleeding episode resolved
  • Severe hemorrhage: A dose sufficient to achieve factor VIII activity of 60-100% of normal for intracranial, intraabdominal, GI, or intrathoracic bleeds, central nervous system bleeds, bleeding in retropharyngeal spaces or iliopsoas sheath, life or limb threatening hemorrhage; may repeat dose 8-24 hr until bleeding risk resolved

Bleeding episodes (Afstyla)

• All ages

  • Mild hemorrhage: A dose sufficient to achieve factor VIII activity of 20-40% of normBal for early hemarthrosis, minor muscle bleeding, or oral bleeds; may repeat dose q12-24hr for at least 1 day, until bleeding episode resolved
  • Moderate hemorrhage: A dose sufficient to achieve factor VIII activity of 30-60% of normal for more extensive hemarthrosis, muscle bleeding or hematoma; may repeat dose q12-24hr for at least 3-4 day, until bleeding episode resolved
  • Severe hemorrhage: A dose sufficient to achieve factor VIII activity of 60-100% of normal for intracranial, intraabdominal, GI, or intrathoracic bleeds, central nervous system bleeds, bleeding in retropharyngeal spaces or iliopsoas sheath, life or limb threatening hemorrhage; may repeat dose 8-24 hr until bleeding risk resolved

Bleeding episodes (Jivi)

• <12 years: Safety and efficacy not established
• There is a higher rate of hypersensitivity in children aged <12 years owing to immune response to PEG

• ≥12 years

  • Mild hemorrhage: 10-20 IU/kg IV to achieve factor VIII activity of 20-40% of normal for early hemarthrosis, superficial muscle or soft tissue and minor oral bleeds; may repeat dose q24-48hr until bleeding episode resolved
  • Moderate hemorrhage: 15-30 IU/kg IV to achieve factor VIII activity of 30-60% of normal for more extensive hemarthrosis, muscle bleeding, or hematoma; may repeat dose q24-48hr until bleeding episode resolved
  • Severe hemorrhage: 30-50 IU/kg IV to achieve factor VIII activity of 60-100% of normal for major hemorrhage including GI bleeding, intracranial, intraabdominal or intrathoracic, CNS, bleeding in the retropharyngeal or retroperitoneal spaces or iliopsoas sheath, live- or limb-threatening hemorrhage; may repeat dose q8-24hr until bleeding episode resolved

Bleeding episodes (Esperoct)

• Aged ≤12 years

  • Mild hemorrhage: 65 IU/kg; 1 dose is typically sufficient
  • Moderate hemorrhage: 65 IU/kg; an additional dose may be administered after 24 hr
  • Severe hemorrhage: 65 IU/kg; additional doses may be administered ~q24hr

Perioperative management, FVIII level required

• Minor surgery: Target of 60-100 IU/dL peak (2100-3500 IU for 70 kg); single bolus within 1 hr of operation; additional dosing q12-24hr PRN for bleeding
• Major surgery: Target of 80-100 IU/dL peak (2800-4200 IU for 70 kg) preop and postop; repeat infusion q6-12hr PRN for wound healing

Perioperative management (Eloctate)

• Minor surgery: 25-40 IU/kg IV; repeat q24hr (age <6 yr q12-24hr) for at least 1 day until healing is achieved; 50-80 IU/dL FVIII level required
• Major surgery: 40-60 IU/kg IV preop; repeat 40-50 IU/kg after 8-24 hr (age <6 yr q6-24hr), and then qDay until adequate wound healing, then continue for at least 7 days; 80-120 IU/dL FVIII level required

Perioperative management (Nuwiq)

• Aged 2-17 years

  • Minor surgery: An IV dose sufficient to achieve Factor VIII activity within 80-100% of normal pre- and postoperatively; may repeat q24hr for least 1 day until healing is achieved
  • Major surgery: An IV dose sufficient to achieve Factor VIII activity within 30-60% of normal pre- and postoperatively for major surgery including intracranial, intraabdominal, or joint replacement therapy; may repeat q8-24hr until adequate wound healing, then continue therapy for at least another 7 days to maintain a Factor VIII activity of 30-60% (IU/dL)

Perioperative management (Adynovate)

• Children (<12 years) have demonstrated higher clearance, a shorter half-life, and lower incremental recovery of factor VIII compared to adults; dose adjustment or more frequent dosing based on per kg body weight may be needed in this population
• Minor surgery: An IV dose of 30-50 IU/kg sufficient to achieve Factor VIII activity within 60-100% of normal pre- and postoperatively; may repeat q24hr for least 1 day until healing is achieved
• Major surgery: An IV dose of 40-60 IU/kg sufficient to achieve Factor VIII activity within 80-120% of normal pre- and postoperatively within 1 hr before operation for major surgery including intracranial, intraabdominal, or joint replacement therapy; may repeat q8-24hr (q6-24 hr for children <12 yr) until adequate wound healing

Perioperative management (Kovaltry)

• Aged ≤12 years

  • Minor surgery: An IV dose sufficient to achieve Factor VIII activity within 30-60% of normal pre- and postoperatively; may repeat q24hr for least 1 day until healing is achieved
  • Major surgery: An IV dose sufficient to achieve Factor VIII activity within 80-100% of normal pre- and postoperatively for major surgery including intracranial, intraabdominal, intrathoracic, or joint replacement therapy; may repeat q8-24hr until adequate wound healing, then continue therapy for at least another 7 days to maintain a Factor VIII activity of 30-60% (IU/dL)

Perioperative management (Afstyla)

• Any age

  • Minor surgery: An IV dose sufficient to achieve Factor VIII activity within 30-60% of normal pre- and postoperatively; may repeat q24hr for least 1 day until healing is achieved
  • Major surgery: An IV dose sufficient to achieve Factor VIII activity within 80-100% of normal pre- and postoperatively for major surgery including intracranial, intraabdominal, intrathoracic, or joint replacement therapy; may repeat q8-24hr until adequate wound healing, then continue therapy for at least another 7 days to maintain a Factor VIII activity of 30-60% (IU/dL)

Perioperative management (Jivi)

• <12 years: Safety and effiacy not established
• There is a higher rate of hypersensitivity in children aged <12 years owing to immune response to PEG

• ≥12 years

  • Minor surgery: 15-30 IU/kg IV to achieve factor VIII level of 30-60% of normal for minor surgery (eg, tooth extraction); may repeat dosage q24hr for at least 1 day until healing is achieved
  • Major surgery: 40-50 IU/kg IV to achieve factor VIII level of 80-100% of normal for major surgery (eg, intracranial, intra-abdominal, or joint replacement); may repeat dosage q12-24hr for at least 1 day until adequate wound healing complete, then continue therapy for at least another 7 days to maintain Factor VIII activity of 30-60% (IU/dL)

Perioperative management (Esperoct)

• Aged ≤12 years

  • Minor surgery: 65 IU/kg; additional dose(s) may be administered after 24 hr if necessary
  • Major surgery: 65 IU/kg; additional doses can be administered ~q24hr for the first week and then ~q48hr until wound healing has occurred

Routine prophylaxis dose

• NovoEight (<12 years): 25-60 IU/kg IV 3x/week, OR 25-50 IU/kg IV every other day
• NovoEight (≥12 years): 20-50 IU/kg IV 3x/week, OR 20-40 IU/kg IV every other day
• Kogenate FS, Helixate FS: 25 IU/kg IV every other day
• Advate: 20-50 IU/kg IV every other day
• Eloctate: 50 IU/kg IV q4days; adjust based on patient response (range: 24-65 IU/kg at 3-5 day intervals); more frequent or higher doses up to 80 IU/kg may be required for children aged <6 years
• Nuwiq (2-11 years): 30-50 IU/kg IV every other day or 3x/week
• Nuwiq (12-17 years): 30-40 IU/kg IV every other day
• Adynovate (≥12 years): 40-50 IU/kg IV 2x/week; adjust dose based on clinical response
• Adynovate (<12 years): 55 IU/kg IV 2x/week; adjust dose based on clinical response, not to exceed 70 IU/kg
• Kovaltry (≤12 years): 25-50 IU/kg IV 2-3 x/week or every other day according to individual requirements
• Afstyla (<12 years): 30-50 IU/kg IV 2-3 times per week Afstyla (≥12 years): 20-50 IU/kg IV 2-3 times per week
• Jivi (≥12 years): 30-40 IU/kg IV 2x/week; based on bleeding episodes, may adjust to 45-60 IU/kg q5days; may further individually adjust to less or more frequent dosing
• Esperoct (≤12 years): 65 IU/kg IV 2 x/week; may further individually adjust to less or more frequent dosing

Dosing Considerations

Children have higher factor VIII clearance compared with adults and may require larger or more frequent dosing

Advate, Kovaltry, Xyntha: Recombinant, plasma/albumin free method products

Nuwiq: B-domain deleted recombinant FVIII derived from a human cell-line, not chemically modified or fused with another protein

Jivi: Not indicated for previously untreated patients, treating von Willebrand disease, or children aged <12 years

The amount of recombinant Factor VIII (in international units [IU]) is specified on each vial for the various products